Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
November 10, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
October 26, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
September 23, 2022 12:29 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
September 19, 2022 18:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
September 13, 2022 17:12 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
September 09, 2022 17:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
September 08, 2022 14:08 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
August 23, 2022 17:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Announces Changes to its Board of Directors
August 09, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
July 25, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment...